SciMax and Knight Therapeutics are Going Live Using SciMax MI (MedInquirer) with Integrations to Argus and Veeva
Princeton, NJ, May 23, 2022 –
After a rigorous selection process, Knight chose SciMax Global’s SciMax MI (also known as MedInquirer) medical information system. SciMax MI is a cloud-based software as a service (SaaS) system. It is a comprehensive, configurable, and validated off-the-shelf system that meets Knight’s Global Medical Information team’s specific business requirements.
In addition to best-of-breed medical information functionality, Knight needed their MI solution to integrate with their safety system AccelSafety (powered by Oracle Argus Safety) and their Veeva CRM. SciMax offers a comprehensive safety and MI platform as well as the only certified integration with Veeva software. The scope of the project included not only the various integrations but also a complete validation suite, end-user and administration training, and all relevant documents.
“Working with the SciMax team was a seamless process from start to finish. SciMax MI has streamlined our business operational activities and helped us to continue to better serve our customers” said Mélanie Groleau, Senior Director of Medical Affairs and Pharmacovigilance at Knight. Knight’s MI department utilizes the fully validated SciMax MI system in multiple countries to document and respond to medical product inquiries, report potential product quality complaints (PQC) to quality assurance, and to report potential adverse events (AEs) to pharmacovigilance.
Over the course of the project, the SciMax team, led by project manager Auvifer Ruelos, worked alongside Knight’s team to finalize specific business requirements, determine business- specific configurations, determine validation deliverables, and set the implementation schedule to ensure a successful launch of the SciMax MI solution with all the required configurations, products and medical information content for use across all regions. “This was both a challenging and highly rewarding project,” says Auvifer, COO of SciMax. “What helped tremendously was the Knight team’s level of engagement and commitment and their ability to quickly review and finalize system requirements.”
SciMax and Techsol continue to provide exceptional fully integrated medical affairs solutions combined with experienced implementation and support services.
About Knight Therapeutics
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.gud-knight.com or www.sedar.com.
About SciMax Global
SciMax Global is an innovative Scientific Communications and Medical Affairs consulting and technology solutions provider in the pharmaceutical industry. With a unified cloud Technology Platform and value-driven Consulting Services, SciMax has proven capabilities to help Pharmaceutical and Life Science organizations manage Medical Affairs program.